Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19 - 02/11/21
, Abdallah Al-Salameh a, b, ⁎ , Samy Hadjadj c, Thomas Goronflot d, Nicolas Wiernsperger e, Matthieu Pichelin c, Ingrid Allix f, Coralie Amadou g, Olivier Bourron h, Thierry Duriez i, Jean-François Gautier j, Anne Dutour k, Céline Gonfroy l, Didier Gouet m, Michael Joubert n, Ingrid Julier o, Etienne Larger p, Lucien Marchand q, Michel Marre r, Laurent Meyer s, Frédérique Olivier t, Gaëtan Prevost u, Pascale Quiniou v, Christelle Raffaitin-Cardin w, Ronan Roussel x, Pierre-Jean Saulnier y, Dominique Seret-Begue z, Charles Thivolet aa, Camille Vatier bb, Rachel Desailloud a, b, Matthieu Wargny d, Pierre Gourdy cc, 1, Bertrand Cariou c, 1for the CORONADO investigators2
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Aims |
Metformin exerts anti-inflammatory and immunosuppressive effects. We addressed the impact of prior metformin use on prognosis in patients with type 2 diabetes hospitalised for COVID-19.
Methods |
CORONADO is a nationwide observational study that included patients with diabetes hospitalised for COVID-19 between March 10 and April 10, 2020 in 68 French centres. The primary outcome combined tracheal intubation and/or death within 7 days of admission. A Kaplan-Meier survival curve was reported for death up to day 28. The association between metformin use and outcomes was then estimated in a logistic regression analysis after applying a propensity score inverse probability of treatment weighting approach.
Results |
Among the 2449 patients included, 1496 were metformin users and 953 were not. Compared with non-users, metformin users were younger with a lower prevalence of diabetic complications, but had more severe features of COVID-19 on admission. The primary endpoint occurred in 28.0% of metformin users (vs 29.0% in non-users, P = 0.6134) on day 7 and in 32.6% (vs 38.7%, P = 0.0023) on day 28. The mortality rate was lower in metformin users on day 7 (8.2 vs 16.1%, P < 0.0001) and on day 28 (16.0 vs 28.6%, P < 0.0001). After propensity score weighting was applied, the odds ratios for primary outcome and death (OR [95%CI], metformin users vs non-users) were 0.838 [0.649−1.082] and 0.688 [0.470−1.007] on day 7, then 0.783 [0.615−0.996] and 0.710 [0.537−0.938] on day 28, respectively.
Conclusion |
Metformin use appeared to be associated with a lower risk of death in patients with diabetes hospitalised for COVID-19.
Il testo completo di questo articolo è disponibile in PDF.Keywords : COVID-19, Death, Mechanical ventilation, Metformin, Propensity score, Type 2 diabetes
Mappa
Vol 47 - N° 5
Articolo 101216- settembre 2021 Ritorno al numero
Articolo precedente
- Association between sleep duration in early pregnancy and risk of gestational diabetes mellitus: a prospective cohort study
- Min Du, Jue Liu, Na Han, Zhiling Zhao, Shusheng Luo, Haijun Wang
- Exposure to persistent organic pollutants and the risk of type 2 diabetes: a case-cohort study
- Dianna J. Magliano, Fanny Rancière, Rémy Slama, Ronan Roussel, Hannu Kiviranta, Xavier Coumoul, Beverley Balkau, Jérémie Botton, the D.E.S.I.R. Study Group
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.